ACE2 | Jotup

Landmark New Publication: the Forgotten Biochemistry 101 of COVID-19

Retrieved on:

Lundi, avril 22, 2024

SALT LAKE CITY, April 22, 2024 /PRNewswire/ -- TrialSite News features a paper published today in Viruses (Basel), authored by an international team of researchers, including two fellows of their nations' academies of sciences (Colleen Aldous, senior author Wendy Hoy) and others who participated in Nobel prize-honored research (Thomas Borody, Morimasa Yagisawa). The publication reveals how coronavirus biochemistry well-established over past decades governs the morbidities of COVID-19, risk factors and therapeutic approaches.

Key Points:

The publication reveals how coronavirus biochemistry well-established over past decades governs the morbidities of COVID-19, risk factors and therapeutic approaches.
The glycan monomer sialic acid, ubiquitous on eukaryotic cell surfaces, serves as the initial attachment point to host cells for the COVID–19 virus—SARS–CoV–2—as well as for other coronaviruses.
In the genetics-centric research environment of recent decades, however, most COVID–19 research ignored this older, well-established biochemistry, focusing instead on SARS–CoV–2 replication and its replication receptor, ACE2.
Three major risk factors for COVID–19 mortality—older age, diabetes and obesity—are each associated with significantly increased RBC aggregation and microvascular occlusion.

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Retrieved on:

Jeudi, avril 4, 2024

Biotechnology, Georgia State University, Messenger, Death, Doctor of Philosophy, SARS-CoV-2, Capsid, ACE2, Combat, Infection, Cancer, Omicron, Vaccine, Antigen

ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company’s next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC.

Key Points:

During his presentation, titled “Vaccine Induction of Broadly-Specific Antibody and T Cell Responses to Combat SARS-CoV-2 Variation”, Dr. Newman described GeoVax’s development program for GEO-CM04S1.
The data presented were generated in collaboration with scientists at Georgia State University using the human ACE2 transgenic mice, one of the “gold standard” small animal models used for studying Covid vaccines.
GEO-CM04S1 incorporates both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce broadly specific antibody and T cell responses.
I anticipate similar findings will be observed in our Phase 2 clinical trials as the studies are unblinded later this year.”

First Mice Engineered to Survive COVID-19 Like Young, Healthy Humans

Retrieved on:

Mercredi, novembre 1, 2023

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

Key Points:

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.
The mice with this genetic change developed symptoms similar to young humans infected with the virus causing COVID-19, instead of dying upon infection as had occurred with prior mouse models.
"This has been a major missing piece in efforts to develop new drugs against this virus."
Boeke also receives consulting fees and royalties from OpenTrons, and holds equity in the company.

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19

Retrieved on:

Mercredi, octobre 4, 2023

AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.

Key Points:

AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.
Aerium is pursuing a mAb combination strategy to defend against future viral evolution.
Aerium is also initiating development of AER005 for potential inclusion in a future product.
The mAbs have been modified to provide long-acting protection and exhibit potent and consistent activity against all previous and predominantly circulating variants.

Now available from Aniara Diagnostica 5-ELISA ACE 2 Antigen For measuring Angiotensin Converting Enzyme 2 (ACE2) antigen in plasma or in any biological fluid

Retrieved on:

Jeudi, août 24, 2023

Use, WEST, Multimedia, Plasma, Diagnosis, Research, ACE2, Vaccine

WEST CHESTER, Ohio, Aug. 24, 2023 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest standards for product quality and cost-efficient delivery.

Key Points:

Aniara Diagnostica is pleased to announce the availability of 5-ELISA ACE2 Antigen kit, a two-site enzyme immunoassay for measuring Angiotensin Converting Enzyme 2 (ACE2) antigen in plasma or in any biological fluid where it must be tested.
WEST CHESTER, Ohio, Aug. 24, 2023 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest standards for product quality and cost-efficient delivery.
The entire Aniara product line is available for purchase at http://www.aniara.com .
The Company distributes products in North America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

Partner Tech Introduces Technology Advanced Self-Checkout Solution for Any Size Retailer

Retrieved on:

Jeudi, juillet 27, 2023

EAS, Partnership, RFID, RSPA, NACS, API, POS, ID, Supermarket, VAR, Checkpoint Systems, System, ISV, ROI, ACE2, SCO, Online shopping

Anaheim, Calif., July 27, 2023 /PRNewswire-PRWeb/ -- Partner Tech USA Inc, a global technology company and innovator of intelligent POS and self-service solutions, is launching ACE2, a next-generation fully integrated self-checkout solution that delivers higher throughput and frictionless shopping. ACE2 combines rich, modular functionality and strong security features with a sleek and space-saving design. Thus, it is an attractive self-checkout solution for many types of retailers, including supermarkets, convenience stores, drug stores, and more.

Key Points:

Anaheim, Calif., July 27, 2023 /PRNewswire-PRWeb/ -- Partner Tech USA Inc , a global technology company and innovator of intelligent POS and self-service solutions, is launching ACE2, a next-generation fully integrated self-checkout solution that delivers higher throughput and frictionless shopping.
Thus, it is an attractive self-checkout solution for many types of retailers, including supermarkets, convenience stores, drug stores, and more.
In partnership with the strategic technology partner Checkpoint Systems , ACE2 also supports EAS tags and RFID.
By teaming up with Partner Tech, retailers will be able to improve customers' shopping experience and increase the ROI of their stores' self-checkout stations."

We found coronaviruses in UK bats -- so far the danger’s minimal but we need to know more about viruses that can spread to humans

Retrieved on:

Mardi, juin 27, 2023

However, we don’t have a good understanding of the diversity of viruses circulating in bat populations in most parts of the world.

Key Points:

However, we don’t have a good understanding of the diversity of viruses circulating in bat populations in most parts of the world.
We also don’t have a good idea of the number of bat viruses that could jump into humans in the future.
This motivated new research, in which we searched for RNA viruses circulating in UK bats.

Studying UK bats

These were mostly from injured or grounded bats rehabilitated by the Bat Conservation Trust.
This strategy didn’t cause hurt or disturbance to any bat we sampled and didn’t increase contact rates between bats and humans.
In the two species of British Rhinolophus bats we also found four sarbecoviruses, the same group of viruses as SARS-CoV-2.
Our study likely underestimates the true diversity of coronaviruses circulating in UK bats since we sequenced only 48 samples and not all bats are infected by all viruses at all times.

Bats as reservoirs for zoonotic viruses

Though, the large number of zoonotic viruses carried by bats may be primarily due to their high species diversity.
So monitoring for viruses shouldn’t only focus on bats, but include other groups of mammals such as rodents, carnivores and ungulates (mammals with hooves).
Read more:
Why it's important to study coronaviruses in African bats
It’s possible COVID was caused by a zoonotic pathogen, and it’s possible it wasn’t.
But improved characterisation of pathogens with zoonotic potential would still allow preemptive design and testing of vaccines and drug compounds against the most threatening zoonotic pathogens.

Experimental Decoy Protects Against SARS-CoV-2 Infection

Retrieved on:

Mercredi, mai 31, 2023

NEW YORK, May 31, 2023 /PRNewswire/ -- An experimental "decoy" provided long-term protection from infection by the pandemic virus in mice, a new study finds.

Key Points:

NEW YORK, May 31, 2023 /PRNewswire/ -- An experimental "decoy" provided long-term protection from infection by the pandemic virus in mice, a new study finds.
Treatment of patients soon after infection was successful in preventing hospitalization and death.
The free-floating "decoy" binds to the virus by its spikes so that it can no longer attach to ACE-2 on cells in airways.
The decoy lowered the virus load in the mice by 100,000-fold, while mice exposed to a non-active control treatment died.

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on:

Mercredi, mai 10, 2023

Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.

Key Points:

Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.
In the first quarter of 2023, the Company entered into a new research collaboration with a biotech company for a fully funded proof-of-concept project to express an enzyme for pharmaceutical applications.
G&A Expenses: General and administrative expenses for the quarter ended March 31, 2023, decreased by 10.6% to approximately $1,480,000 compared to $1,656,000 for the quarter ended March 31, 2022.
Other Income: Other income for the quarter ended March 31, 2023 was from the sale of the equity interest in Alphazyme, LLC.

EverGlade Consulting Funding Alert: Biden Administration Announces Launch of Successor Program to Operation Warp Speed Accompanied by the Release of New Funding Opportunities for the Development of Vaccines and Therapeutics

Retrieved on:

Mercredi, avril 12, 2023

The assays should analyze clinical study samples and measure immune responses to both ancestral SARS-CoV-2 and variants of concern.

Key Points:

The assays should analyze clinical study samples and measure immune responses to both ancestral SARS-CoV-2 and variants of concern.
Assays of interest include lentivirus-based virus neutralization assays, multiplexed antigen panels, and MSD-based ACE2 receptor blocking assays.
"Given the success of Project Warp Speed, it is no surprise that BARDA would try to build on that success," stated EverGlade Consulting Founder, Eric Jia-Sobota.
For additional information about EverGlade Consulting, visit:
View original content to download multimedia: https://www.prnewswire.com/news-releases/everglade-consulting-funding-al...